MedPath

Cabozantinib Demonstrates Promising Results in Neuroendocrine Tumors, Analyst Recommends 'Buy' for Exelixis

• Cabozantinib significantly improved progression-free survival (PFS) in patients with extra-pancreatic neuroendocrine tumors originating from the gastrointestinal tract, showing a 50% increase compared to placebo. • The CABINET trial data presented at the ASCO Gastrointestinal Cancers Symposium highlighted cabozantinib's clinical benefits across various factors, including tumor grade and prior treatments, with a favorable safety profile. • Anticipated FDA approval by April 2025 further supports Exelixis's stock potential, leading analysts to consider it a worthwhile investment opportunity with a projected 17.4% return. • Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL) with a price target of $38.00, based on the promising trial results and potential for growth.

Exelixis's cabozantinib has shown promising results in treating neuroendocrine tumors (NETs), particularly those originating from the gastrointestinal tract. Data from the CABINET trial, presented at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrated a significant improvement in progression-free survival (PFS) for patients with extra-pancreatic NETs. This has led analysts to recommend a 'Buy' rating for Exelixis stock, anticipating potential FDA approval by April 2025.

CABINET Trial Results

The CABINET trial highlighted that patients with extra-pancreatic neuroendocrine tumors experienced a noteworthy 50% increase in PFS compared to placebo. This subgroup represented more than half of the cohort, underscoring cabozantinib’s potential impact in addressing unmet medical needs in this patient population. The clinical benefits extended to various other factors such as tumor grade, functional status, and prior treatments.
The safety profile of cabozantinib in the trial aligned with known expectations, with no new safety concerns identified. This is crucial for establishing the drug's viability as a long-term treatment option for NETs.

Analyst Recommendation

David Lebowitz, an analyst from Citi, maintained a Buy rating on Exelixis (EXEL) with a price target of $38.00. His recommendation is based on the promising trial results and the anticipated FDA approval, projecting a 17.4% return on investment. Another report from JMP Securities released on January 23 also maintained a Buy rating on the stock with a $41.00 price target.

About Cabozantinib

Cabozantinib is an oral tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. It is currently marketed under the brand names Cabometyx and Cometriq for the treatment of various cancers, including renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.

Exelixis Company Overview

Exelixis, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines for cancer treatment. The company's portfolio includes Cabometyx, Cometriq, and Cotellic. Founded in 1994 and headquartered in Alameda, CA, Exelixis is dedicated to providing innovative therapies for patients with cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Exelixis' Zanzalintinib Shows Promise in Early Trials, Positioning It as Potential Cabozantinib Successor

Phase 1 STELLAR-001 trial data indicates that zanzalintinib combined with atezolizumab demonstrates a higher objective response rate, especially in patients without liver metastases.
Zanzalintinib offers improved tolerability compared to cabozantinib, potentially allowing patients to stay on treatment longer with fewer dose adjustments, enhancing overall outcomes.

Phase 1 Trial of Zanza-Atezo Combo Shows Early Promise in Colorectal Cancer, But Questions Remain

Early data from Exelixis's Phase 1 trial evaluating the combination of zanza and atezo in colorectal cancer (CRC) has shown promising results, particularly in patients without liver metastasis. However, the small sample size and uncontrolled nature of the study raise important considerations for the ongoing Phase 3 trial's potential success.

FDA Foregoes Advisory Committee for Cabozantinib's Neuroendocrine Tumor Application

The FDA has canceled the Oncologic Drugs Advisory Committee meeting for Exelixis' cabozantinib sNDA, streamlining the review process.
The sNDA seeks approval for cabozantinib to treat advanced pancreatic and extra-pancreatic neuroendocrine tumors in previously treated adults.

Exelixis Downgraded to Market Perform Despite Price Target Increase to $40

BMO Capital Markets downgraded Exelixis Inc. from Outperform to Market Perform, raising the price target to $40 due to a cautious outlook on the company's growth prospects, despite a 56% stock gain over six months. The focus is on zanzalintinib's trial for colorectal cancer, with success probability increased to 50%, amidst uncertainties from cabometyx's mixed track record.

Ascendis Pharma's Promising Growth Prospects: Buy Rating Backed by Positive Clinical Results

Citi's David Lebowitz maintains a Buy rating on Ascendis Pharma, citing positive clinical trial results for TransCon hGH and expected growth prospects, with a price target of $200.00.

Assertio Therapeutics Receives Buy Rating Following Positive Clinical Trial Results

H.C. Wainwright reaffirms a Buy rating for Assertio Therapeutics, citing promising clinical trial outcomes for ROLVEDON in early-stage breast cancer treatment, with a price target of $4.00.

Cabozantinib Shows Promise in Gastrointestinal Neuroendocrine Tumors: Phase 3 CABINET Subgroup Analysis

Cabozantinib significantly improved progression-free survival (PFS) compared to placebo in patients with advanced gastrointestinal neuroendocrine tumors (GI NETs).
The subgroup analysis of the Phase 3 CABINET study revealed a 50% reduction in the risk of disease progression or death with cabozantinib.

Crinetics Pharmaceuticals' Atumelnant Shows Promise in Phase 2 Trial for Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals' atumelnant demonstrated significant A4 reductions in a Phase 2 trial, positioning it favorably against existing treatments for congenital adrenal hyperplasia (CAH).
The trial showed a rapid onset of action for atumelnant, with substantial A4 reductions evident as early as Week 2 and sustained through Week 12, indicating potential disease-modifying capabilities.

Cabometyx Demonstrates Significant Efficacy in Advanced Neuroendocrine Tumors

The CABINET Phase III trial revealed that Cabometyx significantly reduced the risk of disease progression or death in advanced neuroendocrine tumors (NETs).
In pancreatic NETs, Cabometyx showed a 77% reduction in risk, with median progression-free survival (PFS) of 13.8 months compared to 4.4 months for placebo.

Eli Lilly's Efsitora Shows Promise in Phase III Trial, Challenging Novo Nordisk's Icodec

Eli Lilly's once-weekly insulin efsitora demonstrates successful Phase III trial results, positioning it as a strong competitor to Novo Nordisk's icodec.
The trial showed efsitora's A1C reduction to be non-inferior to daily basal insulins in adults with type 2 diabetes, offering a more convenient dosing schedule.

Reference News

[1]
Exelixis' cabozantinib approval 'certainly positive,' says Citi
markets.businessinsider.com · Mar 26, 2025
[2]
Exelixis's Cabozantinib Shows Promising Results for NET: Analyst Recommends 'Buy'
markets.businessinsider.com · Jan 25, 2025

Citi analyst David Lebowitz maintains a Buy rating on Exelixis (EXEL) with a $38 target, citing cabozantinib's promising...

[3]
Exelixis' cabozantinib approval 'certainly positive,' says Citi
finance.yahoo.com · Mar 27, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy